课题基金 / 基金详情

Altered structure and activity of the RSV attachment glycoprotein produced in primary human airway cells

Altered structure and activity of the RSV attachment glycoprotein produced in primary human airway cells
原代人气道细胞中产生的 RSV 附着糖蛋白的结构和活性发生改变
批准号:
9911262
负责人:
Tiffany King
金额:
$3.33万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-27 至 2021-05-15

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT Respiratory syncytial virus (RSV) is the leading cause of hospitalization of children under one year of age, but there are no approved vaccines or effective anti-viral treatments. RSV infects epithelial cells in the upper and lower respiratory tracts causing severe bronchiolitis in young children and adults. The use of primary human bronchial epithelial cultures (HBEC) has enabled us to identify its target cell type (ciliated) as well as better understand its pathogenesis in an ex vivo model. HBEC are grown at an air-liquid interface allowing differentia- tion of progenitor cells into pseudostratified, ciliated and mucus-producing cultures that mirror the human air- ways. We have found that RSV produced in HBEC (RSV/HBE) contains a much larger version of its attachment (G) glycoprotein (G/HBE; 170 kDa) than the “classical” 90 kDa form produced in immortalized cells. We have evidence consistent with this size difference being due to extra glycosylation of the G protein in HBEC compared to HEp-2 (immortalized) cells. We have also found that RSV/HBEC is 100-fold less infectious for HEp-2 cells compared to HBEC, based on qRT-PCR quantified viral genomes relative to the infectivity of GFP-expressing RSV. We will identify the structural reason for the larger G produced in HBEC and determine the importance of G glycosylation for infection of HBEC. The results may elucidate the role of G in vivo, improve RSV vaccine production and allow much more efficient isolation of RSV from clinical samples without selection for modified viruses able to grow in HEp-2 cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
基于多重精准选择性碳氢官能化合成策略的抗A549/HepG2活性先导化合物发现及其作用靶标研究
  • 批准号:
    22007020
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    周志
  • 依托单位:
导向抗HepG2/A549先导化合物发现和结构优化的多重精准选择性C-H键官能化反应研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2019
  • 负责人:
    周志
  • 依托单位:
内蒙古白云鄂博稀土矿区大气可吸入颗粒物对A549细胞毒理研究
  • 批准号:
    81473017
  • 项目类别:
    面上项目
  • 资助金额:
    66.0万元
  • 批准年份:
    2014
  • 负责人:
    孙涓
  • 依托单位:
用于识别癌细胞A549的磁共振和荧光双功能探针的研究